Triumeq Pd (Abacavir/Dolutegravir/Lamivudi) Patent Expiration, LOE Window & CMS Spending

Triumeq Pd (Abacavir/Dolutegravir/Lamivudi) by GSK: FDA Orange Book core substance LOE 2030-06-08, 0 AB generics, $740K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN215413 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-06-08
Last Listed Patent or Exclusivity Date2030-06-08
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$740K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$740K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.